Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AXSM with free AI briefings, catalyst countdowns, and dilution alerts.

AXSM · Axsome Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$313.9M Cash on Hand
44.4mo Cash Runway
9.6% Short Interest
$264.62 Analyst Target (21)
Follow AXSM by email Get an email when AXSM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AXSM, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-05-01 AXS-12 cataplexy in narcolepsy NDA 66%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What AXSM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Solriamfetol
FDA approved Mar 2019 · Sunosi
Insomnia Phase 4 · NCT05838430 Completed
Bupropion Major Depressive Disorder Phase 4 · NCT06223880 Recruiting
Dextromethorphan/Bupropion Tablet AXS-05 Major Depressive Disorder Phase 4 · NCT06223880 Recruiting
AXS-02 Osteoarthritis, Knee Phase 3 · NCT02746068 Unknown
Solriamfetol Dose A ADHD Phase 3 · NCT07717892 Recruiting
Rizatriptan Migraine Phase 3 · NCT03896009 Completed
Solriamfetol Dose B ADHD Phase 3 · NCT07717892 Recruiting
AXS-14 (Esreboxetine) Fibromyalgia Phase 3 · NCT07398417 Recruiting
AXS-12 (reboxetine) Narcolepsy Phase 3 · NCT05059223 Completed
AXS-07 Migraine Phase 3 · NCT04163185 Completed
Dextromethorphan Hydrobromide, Bupropion… Major Depressive Disorder (MDD) Phase 2 · NCT07523048 Recruiting
Other prescription wake-promoting medications… Narcolepsy N/A · NCT06413420 Recruiting

Also used in these trials (approved or third-party drugs, not AXSM's own candidates): Meloxicam, Bupropion Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AXSM holds $313.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $21.2M/quarter from operations, an estimated runway of 44.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AXSM files for a raise →

👥 Who Owns AXSM

Insiders 15% Institutions (642 holders) 75% Public and other holders 10%
HolderTypeShares% of sharesAs of
Herriot Tabuteau
Chief Executive Officer, Director, 10% o · +289,854 options
Insider 7,351,729 13.98% 2026-08-05
BlackRock, Inc. Institution (13G, 5%+) 2,736,503 5.20% 2026-06-30
Vanguard Capital Management LLC Institution (13F) 2,007,061 3.82% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 1,972,645 3.75% 2026-09-30
Invesco Ltd. Institution (13F) 1,930,336 3.67% 2026-09-30
FMR, LLC Institution (13F) 1,444,439 2.75% 2026-09-30
Two Sigma Investments, LP Institution (13F) 1,110,902 2.11% 2026-09-30
Geode Capital Management, LLC Institution (13F) 1,010,373 1.92% 2026-09-30
UBS Group AG Institution (13F) 849,766 1.62% 2026-09-30
State Street Corporation Institution (13F) 823,330 1.57% 2026-09-30
Deep Track Capital, Lp Institution (13F) 800,000 1.52% 2026-09-30
Franklin Resources, Inc. Institution (13F) 746,254 1.42% 2026-09-30

Share count 52,599,985 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-03
filed 2026-09-03
Jacobson Mark L.
Sale (S) 10,000 $208.65 0
2026-09-03
filed 2026-09-03
Jacobson Mark L.
Option exercise (M) 10,000 $12.95 10,000
2026-09-03
filed 2026-09-03
Jacobson Mark L.
Option exercise (M) 10,000 – –
2026-08-06
filed 2026-08-07
TABUTEAU HERRIOT
Option exercise (M) 4,660 – –
2026-08-06
filed 2026-08-07
TABUTEAU HERRIOT
Sale (S) 4,660 $213.95 7,229

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-04-30 AUVELITY sNDA +14.6% +12.9% +21%

Browse all historical PDUFA outcomes →

Get the full AXSM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AXSM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.